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Abstract The objective of this study is to investigate the
progression of predominantly choreatic and hypokinetic-
rigid signs in Huntington’s disease (HD) and their rela-
tionship with cognitive and general functioning over time.
The motor signs in HD can be divided into predominantly
choreatic and hypokinetic-rigid subtypes. It has been
reported in cross-sectional studies that predominantly
choreatic HD patients perform better on functional and
cognitive assessments compared to predominantly
hypokinetic-rigid HD patients. The course of these motor
subtypes and their clinical profiles has not been investi-
gated longitudinally. A total of 4135 subjects who partic-
ipated in the European HD Network REGISTRY study
were included and classified at baseline as either predom-
inantly choreatic (n = 891), hypokinetic-rigid (n = 916),
or mixed-motor (n = 2328), based on a previously used
method. The maximum follow-up period was 6 years. The
mixed-motor group was not included in the analyses.
Linear mixed models were constructed to investigate
changes in motor subtypes over time and their relationship
with cognitive and functional decline. Over the 6-year
follow-up period, the predominantly choreatic group
showed a significant decrease in chorea, while hypokinetic-
rigid symptoms slightly increased in the hypokinetic-rigid
group. On the Total Functional Capacity, Stroop test, and
Verbal fluency task the rate of change over time was sig-
nificantly faster in the predominantly choreatic group,
while on all other clinical assessments the decline was
comparable for both groups. Our results suggest that
choreatic symptoms decrease over time, whereas hypoki-
netic-rigid symptoms slightly increase in a large cohort of
HD patients. Moreover, different motor subtypes can be
related to different clinical profiles.
Electronic supplementary material The online version of this
article (doi:10.1007/s00415-016-8233-x) contains supplementary
material, which is available to authorized users.
& M. Jacobs
m.jacobs@lumc.nl
1 Department of Neurology, Leiden University Medical Center,
Albinusdreef 2, 2333 ZA Leiden, The Netherlands
2 Center for Human Drug Research, Leiden, The Netherlands
3 Department of Medical Statistics, Leiden University Medical
Center, Leiden, The Netherlands
4 Department of Neurology, Universita` Cattolica del Sacro
Cuore, Rome, Italy
5 Fondazione Don Carlo Gnocchi, Milan, Italy
6 Department of Neurology, University of Bern, Bern,
Switzerland
7 Faculty of Medical and Human Sciences, Institute of Human
Development, University of Manchester, Manchester, UK
8 Manchester Center of Genomic Medicine, St. Mary’s
Hospital, Central Manchester University Hospitals NHS
Foundation Trust and Manchester Academic Health Science
Center, Manchester, UK
9 George Huntington Institute, Muenster, Germany
10 Department of Radiology, University of Muenster, Muenster,
Germany
11 Department of Neurodegenerative Diseases and
Hertie-Institute for Clinical Brain Research,
University of Tuebingen, Tuebingen, Germany
12 Department of Neurology, Ruhr-University Bochum,
Bochum, Germany
123
J Neurol
DOI 10.1007/s00415-016-8233-x
Keywords Huntington’s disease  Chorea  Hypokinetic 
Neuropsychological assessment
Introduction
Huntington’s disease (HD) is an autosomal dominant
neurodegenerative disorder characterized by motor dis-
turbances, cognitive dysfunction and psychiatric symp-
toms [1, 2]. When the disease progresses, motor
impairments increase and patients become more
impaired in their daily-life activities [2]. The primary
motor disturbances in HD are generally categorized as
involuntary choreatic movements [2]. However,
hypokinesia is also a core component of HD [3–5], and
cannot solely be attributed to medication usage [4]. It
has been reported that chorea is often more pronounced
in patients with early stage HD, whereas in advanced
stages of HD hypokinetic symptoms become more
dominant [6–8]. However, the clinical motor phenotype
is heterogeneous and chorea and hypokinesia can also
co-exist [9].
Another clinical feature of HD is the decline in cog-
nitive functioning, especially in the executive domain
[10, 11]. These cognitive deficits can be present years
before motor signs become overt [12]. To date, a
growing number of studies have focused on the rela-
tionship between motor, functional and cognitive
impairments [4, 13–17]. Recently, a cross-sectional
study showed that predominantly choreatic HD patients
perform better on general and cognitive assessments
compared to predominantly hypokinetic-rigid HD
patients, and that this cannot be explained by differences
in age or disease duration [13]. This suggests that chorea
is associated with less cognitive and global impairment
than hypokinesia. However, the course of motor symp-
toms has not been studied longitudinally. Therefore, we
investigated the progression of motor symptoms over
time in different motor subtypes and examined their
relationship with cognitive and functional decline to get
a better understanding of the clinical course.
Methods
Data of subjects with a confirmed Cytosine-Adenine-
Guanine (CAG) repeat length of C36 on the larger allele
and a total motor score (TMS) of[5 on the Unified HD
Rating Scale (UHDRS) [18] at baseline, who participated
in the REGISTRY study of the European HD Network
(EHDN) were used for this study. The local medical ethics
committee approved the study and written informed con-
sent was obtained from all participants.
All subjects completed at least one follow-up visit, with
the TMS rated five or higher during all follow-up visits, to
ensure the motor presentation of HD. The maximum fol-
low-up period in this study was 6 years. Subjects with a
disease onset before the age of 21 were considered juvenile
HD and were excluded from the analyses. A total of 4135
subjects fulfilled the criteria for this study. The classifica-
tion into motor subtypes at baseline was based on the
method used in our previous cross-sectional study [13].
Total chorea and total hypokinetic-rigid scores were cal-
culated by adding items of the UHDRS, with a maximum
of 28 for each score. For the hypokinetic-rigid score, items
6, 7, 9, and 10 of the UHDRS were added. Item 12 of the
UHDRS was used to calculate the choreatic score. The
difference between the two total scores had to be greater
than one standard deviation (i.e. 4 points) to divide the
predominantly subtypes. A subject was considered mixed-
motor if the difference was smaller than one standard
deviation. This classification resulted in 891 predominantly
choreatic, 916 predominantly hypokinetic-rigid, and 2328
mixed-motor subjects at baseline. Disease burden was
calculated using the formula (age * (CAG repeat length -
35.5)) [19]. Subjects were categorized into disease stages
(1–5) based on the UHDRS total functional capacity (TFC)
score, which is a measure to assess general functioning
(range 0–13) [20]. The cognitive battery consisted of the
written Symbol Digit Modalities test (SDMT), Stroop test
(color, word, and interference), and Verbal fluency task. Of
the 4135 subjects, a total of 2446 subjects (436 predomi-
nantly hypokinetic-rigid, 554 predominantly choreatic,
1456 mixed-motor) completed at least one cognitive task at
baseline and at least one follow-up visit. These subjects
were included in the analyses regarding the relationship
between motor subtypes and clinical measures over time.
Statistical analyses
IBM Statistical Package for the Social Sciences (SPSS) 20
for Windows was used for data analyses. Group compar-
isons at baseline were performed using parametric (inde-
pendent sample t tests) and non-parametric tests (v2 test
and Mann–Whitney U test). The use of neuroleptics was
scored as ‘0 = present’ or ‘1 = absent’. An overview of
medication considered neuroleptics is reported in Supple-
mentary Material 1.
A multilevel regression model (i.e., linear mixed
model), adjusting for age at baseline, gender, CAG repeat
length, and TMS was constructed to investigate the course
of the different motor subtypes over time. Since we were
primarily interested in the differences between the pre-
dominant motor subtypes, the mixed-motor group was not
included in the analyses. Differences between total
hypokinetic-rigid and total chorea scores (total chorea -
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total hypokinetic-rigid) from each time point were used as
outcome variable. Negative scores indicated more
hypokinetic-rigid symptoms, while positive scores indi-
cated more choreatic symptoms. Time was measured in
months since baseline. To account for the correlation
between repeated measurements on the same subject, a
random intercept and random time effect (slope) per sub-
ject was used. To investigate the relationship between
motor subtypes and clinical measures, separate linear
mixed models, adjusting for age at baseline, gender, CAG
repeat length, TMS, and years of education were con-
structed. Total scores per cognitive assessment and the
TFC were used as outcome variables. For all analyses an
unstructured covariance for the random intercepts and
random slopes was used. Differences at baseline and rate of
change (i.e., slope) between both motor groups were
compared.
Results
Demographic data at baseline are shown in Table 1. The
predominantly hypokinetic-rigid group was significantly
younger, more often female, had higher CAG repeat
lengths, a longer disease duration, higher disease burden
scores, lower TFC scores, and a higher TMS at baseline
compared to the choreatic group. There was no difference
between the two groups in number of subjects using
neuroleptics.
The linear mixed model, adjusted for age at baseline,
gender, CAG repeat length, and TMS showed significantly
lower baseline scores for the predominantly hypokinetic-
rigid group on the motor difference score (Table 2). The
predominantly choreatic group showed a more rapid
decline on the motor difference score over the 6-year fol-
low-up period compared to the hypokinetic-rigid group
(b = 0.11, SE = 0.01, p value\0.001) (Fig. 1). There was
a significant effect of time for both groups (b = -0.12,
SE = 0.01, p value\0.001).
Linear mixed models adjusted for age at baseline, gen-
der, CAG repeat length, TMS, and years of education
showed lower baseline scores for the predominantly
hypokinetic-rigid group compared to the predominantly
choreatic group on all clinical measures (Table 2). For all
assessments there was a significant effect of time, with both
groups deteriorating (data not reported in Table 2). Sig-
nificant differences in change over time between the two
groups were observed for the TFC, Stroop word reading
(SWRT), and Verbal fluency task, with the choreatic group
showing a slightly faster rate of decline on these tasks
(Table 2; Fig. 2). Overall, the predominantly choreatic
group had better performances over time than the pre-
dominantly hypokinetic-rigid group on all clinical assess-
ments (Fig. 2).
Table 1 Demographics of whole group and separate motor groups at baseline
Whole group Hypokinetic-rigid Choreatic p value hypokinetic-rigid
vs choreatic
N 4135 916 891
Age, years 51.8 (11.8) 51.8 (12.5) 53.1 (11.6) 0.025
Gender, m/f (%m) 1998/2137 (48.3) 419/497 (45.7) 479/412 (53.8) \0.005
Neuroleptics, y/n (%y) 3393/742 (82.1) 762/154 (83.2) 743/148 (83.4) 0.909
CAG repeat length 44.0 (3.4) 44.8 (3.8) 43.5 (3.2) \0.001
Disease duration, years 6.4 (5.3) 7.8 (5.9) 6.1 (4.9) \0.001
Disease burden 409.1 (107.2) 440.2 (118.6) 394.7 (102.9) \0.001
UHDRS TMS 35.9 (20.0) 47.2 (22.1) 34.7 (17.2) \0.001
UHDRS TFC 9.0 (0–13) 5.0 (0–13) 10.0 (0–13) \0.001
HD stage (%) N = 4005 N = 887 N = 864
1 1382 (34.5) 120 (13.5) 373 (43.2)
2 1309 (32.7) 223 (25.1) 290 (33.6)
3 954 (23.8) 305 (34.4) 169 (19.6)
4 293 (7.3) 190 (21.4) 29 (3.4)
5 67 (1.7) 49 (5.5) 3 (0.3)
Data are mean (SD) for continuous variables, median (range) for UHDRS TFC, and number (%) for gender, neuroleptics, and HD stage. Analyses
are independent sample t tests, except for UHDRS TFC (Mann–Whitney U test), gender and neuroleptics (v2 test). Number (%) of HD stages are
based on different sample sizes due to missing data
CAG Cytosine-Adenine-Guanine, UHDRS TMS Unified Huntington’s Disease Rating Scale Total Motor Score, UHDRS TFC Unified Hunt-
ington’s Disease Rating Scale Total Functional Capacity, HD Huntington’s disease
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Secondary analyses performed in the non-medication
group (n = 302) showed similar significant results for both
motor subtypes on all outcome variables compared to the
whole group analyses (data not reported).
Discussion
This longitudinal study in a large cohort of HD patients
showed that there is a significant difference in the pro-
gression of motor symptoms between predominantly
hypokinetic-rigid and predominantly choreatic subjects
over a 6-year follow-up period. Also, an association
between motor subtypes and clinical assessments was
observed.
The predominantly choreatic group showed a more rapid
decline on the motor difference score compared to the
hypokinetic-rigid group. This suggests that motor phenotype
can be a predictor for a different progression of motor
symptoms, with the predominantly choreatic group showing
a decrease in chorea and the hypokinetic-rigid group a slight
increase of hypokinetic-rigid signs during the course of 6
years. Thus, the progression of motor symptoms is not
uniform for both subtypes. These results strengthen the ideas
proposed in previous studies stating that the presence of
chorea is often more pronounced in early HD stages, and
slowly decreases with time [7, 8]. The observed differences
cannot be explained by differences in age at baseline, since
these were accounted for in the analyses. Moreover, since
we observed an effect of time for both groups, our results do
not seem to indicate a regression to the mean phenomenon.
Our study is the first study to investigate the course of motor
phenotypes longitudinally and to relate these phenotypes
with cognitive and functional assessments. The differences
between both groups at baseline for all cognitive and
Table 2 Baseline and slope differences for the hypokinetic-rigid vs
choreatic group
Hypokinetic-rigid vs choreatic p value
Motor course
Baseline difference -14.95 (0.21)** \0.001
Slope difference 0.11 (0.01)** \0.001
TFC score
Baseline difference -2.31 (0.14)** \0.001
Slope difference 0.02 (0.00)** \0.001
SDMT
Baseline difference -4.44 (0.65)** \0.001
Slope difference 0.02 (0.01) 0.100
Stroop color reading
Baseline difference -6.86 (0.83)** \0.001
Slope difference 0.03 (0.02) 0.098
Stroop word reading
Baseline difference -11.11 (1.12)** \0.001
Slope difference 0.08 (0.03)* 0.003
Stroop interference
Baseline difference -4.64 (0.59)** \0.001
Slope difference 0.02 (0.02) 0.137
Verbal fluency
Baseline difference -3.98 (0.70)** \0.001
Slope difference 0.03 (0.01)* 0.021
Shown are parameter estimates (SE) from the linear mixed models
TFC total functional capacity, SDMT Symbol Digit Modalities test
* p\ 0.05, ** p\ 0.001 indicate significant differences in the
hypokinetic-rigid group compared to the choreatic group
Fig. 1 Predicted values (left)
and fitted longitudinal curves
(right) of the motor difference
score for each motor subgroup.
Predicted values and
longitudinal curves are based on
the linear mixed
model. UHDRS Unified
Huntington’s Disease Rating
Scale
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functional assessments indicates that predominantly chore-
atic subjects perform better on clinical assessments com-
pared to predominantly hypokinetic-rigid subjects. This is
consistent with the results reported in our previous cross-
sectional study [13]. At baseline, there were significantly
more females, lower TFC scores, and a higher UHDRS TMS
observed in the predominantly hypokinetic-rigid group
compared to the choreatic group. Gender has been associ-
ated with differences in disease progression and UHDRS
TMS, with females showing poorer scores and faster pro-
gression rates compared to men [21]. These results might be
related to the differences reported in our study. However, the
longitudinal analyses in our study were adjusted for gender
and TMS, so baseline differences between the groups cannot
explain the different progression of motor symptoms that
was observed between both subtypes. Future studies should
be conducted to explore the influence of gender on motor
subtype to increase the knowledge about differences in
progression rate and phenotypes.
On the TFC, SWRT, and Verbal fluency task a signifi-
cant difference in rate of change over time between the two
groups was found, which implies that the course of cog-
nitive deterioration can differ for each motor subtype. The
predominantly choreatic group showed a slightly faster
decline on these three tasks compared to the hypokinetic-
rigid group. This suggests that the decline in cognitive and
general functioning might be more rapid in this group
compared to the hypokinetic-rigid group. These differences
in rate of change over time could potentially be the result
of the large study cohort and the linear design of the
analyses, and should be interpreted with caution. However,
it should be noted that on all other tasks the change over
time between both groups was comparable. During the
whole 6-year follow-up period, the predominantly chore-
atic group continued to perform better than the hypoki-
netic-rigid group on all clinical assessments. Although both
groups showed a deterioration in cognitive and functional
performances, the differences between the motor subtypes
observed at baseline remained during the course of 6 years.
These findings are consistent with previous studies
reporting that hypokinesia is associated with cognitive and
functional impairments [3, 4, 14, 15]. The lack of a rela-
tionship between chorea and cognitive functioning that is
often reported [15, 17], might be explained by the fact that
choreatic patients perform better on these assessments
during the course of the disease. Thus, motor phenotype
might be a predictor for differences in cognitive and
functional profiles. This should be considered in the future
development of clinical trials and in choosing the right
clinical endpoints. Including only subjects with a particular
Fig. 2 Fitted longitudinal curves for all clinical assessments for each motor subgroup. SDMT Symbol Digit Modalities test, SCNT Stroop color
naming test, SWRT Stroop word reading test, SIT Stroop interference test, TFC total functional capacity
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motor phenotype could potentially affect the outcome of a
clinical trial, since the performances of each phenotype
might differ.
Some limitations of our study should be mentioned. Due
to the longitudinal nature of this study it is likely that
subjects who show the most rapid cognitive decline are lost
to follow-up, which makes our study more prone to attri-
tion bias. Additionally, the cognitive assessments we used
can only provide information about certain cognitive
domains. Including a more extensive cognitive battery
might provide insights into other cognitive domains that
are also affected in HD. Although there were no differences
between the two motor subgroups in the use of neuroleptics
at baseline, and secondary analyses in the non-medication
group showed similar results for both subgroups compared
to the whole group analyses, we did not investigate the
influence of medication usage on the classification of motor
subtypes. The REGISTRY study provides limited infor-
mation about treatment dosage and duration, which com-
plicates the analyses of medication usage. Future studies
should be conducted investigating the relation between
medication and motor phenotypes more thoroughly, since it
might induce hypokinetic symptoms. This could potentially
lead to a misclassification of subjects into the hypokinetic-
rigid group. The mixed-motor group was the largest group
in our study, which indicates that most patients will express
both chorea and hypokinetic-rigid symptoms. Investigating
the characteristics of this group could perhaps provide
more insight into the changes in motor and clinical scores
over time for an extensive amount of patients.
In conclusion, this longitudinal study found that chore-
atic symptoms decrease over time, whereas hypokinetic-
rigid symptoms slightly increase in a large cohort of HD
patients. Moreover, different motor subtypes can be related
to different clinical profiles.
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